From: Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
Non–Down Syndrome | Down Syndrome | |||
---|---|---|---|---|
Parameter | n | Mean (SD) | n | Mean (SD) |
mPAP, mm Hg | 184 | 61.5 (23.0) | 47 | 63.6 (16.7) |
mSAP, mm Hg | 184 | 75.3 (14.3) | 47 | 67.9 (12.5) |
RAP, mm Hg | 184 | 8.3 (5.1) | 47 | 7.5 (2.8) |
mPAP/mSAP | 184 | 0.8 (0.3) | 47 | 0.9 (0.2) |
PCWP, mm Hg | 183 | 9.8 (3.8) | 47 | 9.4 (2.9) |
CI, L/min/m2 | 181 | 3.4 (1.5) | 45 | 3.6 (2.3) |
PVRI, dyn∙s/cm5/m2 | 177 | 1441.3 (1052.7) | 45 | 1638.4 (1273.2) |
SVRI, dyn∙s/cm5/m2 | 181 | 1822.4 (860.1) | 45 | 1669.0 (852.6) |
PVRI/SVRI | 176 | 0.8 (0.7) | 45 | 1.2 (1.3) |
sPAP/sBP | 184 | 0.9 (0.3) | 47 | 0.9 (0.2) |
dPAP/dBP | 184 | 0.7 (0.3) | 47 | 0.8 (0.2) |
Peak VO2, mL/kg/min | 113 | 18.4 (4.2) | 2 | 12.4 (0.9) |
Time to maximum peak VO2 | 113 | 466.7 (133.5) | 2 | 445.0 (183.9) |
% Predicted peak VO2 | 113 | 46.7 (11.4) | 2 | 36.0 (5.1) |
WHO Functional Class, n (%) | N = 183 | N = 48 | ||
Class I | 57 (31) | 18 (38) | ||
Class II | 95 (52) | 25 (52) | ||
Class III | 30 (16) | 5 (10) | ||
Class IV | 1 (1) | 0 |